Dasatinib treatment long-term results among
imatinib-resistant/intolerant patients with chronic phase
chronic myeloid leukemia are favorable in daily clinical
practice

J 2021

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

ŽÁČKOVÁ, Daniela; Hana KLAMOVA; Petra BELOHLAVKOVA; Lukas STEJSKAL; Tereza NEČASOVÁ et al.

Základní údaje

Originální název

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Autoři

Vydání

LEUKEMIA & LYMPHOMA, LONDON, TAYLOR & FRANCIS, 2021, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.996

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00120810

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Chronic myeloid leukemia; chronic phase; imatinib; dasatinib; second line; daily clinical practice

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 4. 2024 14:12, Mgr. Tereza Miškechová

Anotace

V originále

To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients withBCR-ABL1transcript level <= 10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.

Návaznosti

MUNI/A/1395/2019, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VII (Akronym: VýDiTeHeMa VII)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VII, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

ŽÁČKOVÁ, Daniela; Hana KLAMOVA; Petra BELOHLAVKOVA; Lukas STEJSKAL; Tereza NEČASOVÁ; Lukáš SEMERÁD; Barbora WEINBERGEROVÁ; Dana SRBOVA; Jaroslava VOGLOVA; Petra ČIČÁTKOVÁ; Zuzana ŠUSTKOVÁ; Tomáš HORŇÁK; Jana BARANOVÁ; Jiřina PROCHÁZKOVÁ a Jiří MAYER. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. LEUKEMIA & LYMPHOMA. LONDON: TAYLOR & FRANCIS, 2021, roč. 62, č. 1, s. 194-202. ISSN 1042-8194. Dostupné z: https://doi.org/10.1080/10428194.2020.1827242.

@article{1695400,
   author = {Žáčková, Daniela and Klamova, Hana and Belohlavkova, Petra and Stejskal, Lukas and Nečasová, Tereza and Semerád, Lukáš and Weinbergerová, Barbora and Srbova, Dana and Voglova, Jaroslava and Čičátková, Petra and Šustková, Zuzana and Horňák, Tomáš and Baranová, Jana and Procházková, Jiřina and Mayer, Jiří},
   article_location = {LONDON},
   article_number = {1},
   doi = {https://doi.org/10.1080/10428194.2020.1827242},
   keywords = {Chronic myeloid leukemia; chronic phase; imatinib; dasatinib; second line; daily clinical practice},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice},
   url = {https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242},
   volume = {62},
   year = {2021}
}

TY  - JOUR
ID  - 1695400
AU  - Žáčková, Daniela - Klamova, Hana - Belohlavkova, Petra - Stejskal, Lukas - Nečasová, Tereza - Semerád, Lukáš - Weinbergerová, Barbora - Srbova, Dana - Voglova, Jaroslava - Čičátková, Petra - Šustková, Zuzana - Horňák, Tomáš - Baranová, Jana - Procházková, Jiřina - Mayer, Jiří
PY  - 2021
TI  - Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
JF  - LEUKEMIA & LYMPHOMA
VL  - 62
IS  - 1
SP  - 194-202
EP  - 194-202
PB  - TAYLOR & FRANCIS
SN  - 10428194
KW  - Chronic myeloid leukemia
KW  - chronic phase
KW  - imatinib
KW  - dasatinib
KW  - second line
KW  - daily clinical practice
UR  - https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
L2  - https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
N2  - To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients withBCR-ABL1transcript level <= 10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
ER  -

ŽÁČKOVÁ, Daniela; Hana KLAMOVA; Petra BELOHLAVKOVA; Lukas STEJSKAL; Tereza NEČASOVÁ; Lukáš SEMERÁD; Barbora WEINBERGEROVÁ; Dana SRBOVA; Jaroslava VOGLOVA; Petra ČIČÁTKOVÁ; Zuzana ŠUSTKOVÁ; Tomáš HORŇÁK; Jana BARANOVÁ; Jiřina PROCHÁZKOVÁ a Jiří MAYER. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: TAYLOR \&{} FRANCIS, 2021, roč.~62, č.~1, s.~194-202. ISSN~1042-8194. Dostupné z: https://doi.org/10.1080/10428194.2020.1827242.

Přehled o publikaci